Granules India Opens Two Centres of Excellence at IIT Hyderabad
Granules India, a prominent player in the pharmaceutical industry, has inaugurated two advanced Centres of Excellence (CoE) at the Technology Research Park of IIT Hyderabad. This strategic move is aimed at enhancing the company’s capabilities in peptide development and particle engineering, which are critical areas for the future of pharmaceutical innovation.
Overview of the Centres of Excellence
The two Centres of Excellence established by Granules India are:
- Ascelis Center of Excellence for Peptide Development and Characterisation
- Granules Center of Excellence for Particle Engineering
Ascelis Center of Excellence for Peptide Development and Characterisation
The Ascelis Center, which operates under Ascelis Peptides, the Contract Development and Manufacturing Organization (CDMO) arm of Granules, is the first facility of its kind in India. This center is dedicated to the development of cosmetic, therapeutic, and pharmaceutical peptides.
Equipped with advanced technologies, the center focuses on:
- Primary, secondary, and tertiary structure characterisation of peptides
- Integration of analytical and process development capabilities
- Collaboration with Senn Chemicals, a Swiss-based R&D facility
Granules Center of Excellence for Particle Engineering
The Granules Center of Excellence for Particle Engineering aims to advance research in polymorphs, material science, and novel drug delivery systems. This center replaces previous external and ad-hoc development processes with a dedicated research platform that offers:
- First-to-file opportunities in drug development
- Enhanced formulation performance
- Support for the creation of proprietary technologies for regulated markets
Significance of the Centres
According to Krishna Prasad Chigurupati, Chairman and Managing Director of Granules India, the launch of these Centres of Excellence significantly strengthens the company’s capabilities in two critical areas: peptides and advanced material sciences. He stated, “These areas will define the next wave of pharmaceutical innovation.”
Chigurupati emphasized that with specialized infrastructure and deep scientific expertise, Granules India is enhancing its CDMO ambitions, accelerating breakthrough development, and building differentiated technologies. This strategic initiative is expected to elevate the company’s global competitiveness and deliver meaningful value to partners and patients worldwide.
Collaboration and Future Prospects
The collaboration between the new centers and the Swiss-based Senn Chemicals is particularly noteworthy. Senn Chemicals is known for its expertise in peptide synthesis and development, and this partnership will enable Granules India to strengthen its integrated global peptide offerings while reducing reliance on external partners.
As the pharmaceutical industry continues to evolve, the demand for innovative peptide-based therapies is on the rise. The establishment of these Centres of Excellence positions Granules India to capitalize on this growing market, offering advanced solutions that meet the needs of both cosmetic and therapeutic applications.
Conclusion
The opening of the two Centres of Excellence at IIT Hyderabad marks a significant milestone for Granules India. By investing in advanced research and development capabilities, the company is not only enhancing its operational efficiency but also contributing to the broader pharmaceutical landscape. As the industry moves toward more specialized and effective treatments, Granules India is poised to play a pivotal role in shaping the future of healthcare.
Note: The information in this article is based on the latest updates from Granules India and reflects the company’s ongoing commitment to innovation and excellence in the pharmaceutical sector.
